Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer

BackgroundHER2-targeted therapy provides survival benefits to HER2-mutant non-small cell lung cancer (NSCLC). A better understanding of the clinical and genomic characterization of treatment-naïve HER2-positive NSCLC, as well as the efficacy of and resistance to HER2-targeted therapy in HER2-altered...

Full description

Bibliographic Details
Main Authors:	Yanjie Han, Yuanyuan Xiong, Tao Lu, Rongrong Chen, Yuan Liu, Hui Tang, Ruixuan Geng, Yingyi Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Oncology
Subjects:	HER2 non-small cell lung cancer HER2-TKI resistance mechanism targeted sequencing
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1121708/full

Similar Items

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
by: Yan Wang, et al.
Published: (2018-03-01)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
by: Arenda D. Meedendorp, et al.
Published: (2018-05-01)

HER2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation
by: Martyna Zielińska, et al.
Published: (2020-06-01)

HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies
by: Emma Loeffler, et al.
Published: (2023-12-01)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
by: Jing Ma, et al.
Published: (2022-07-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies
by: Natalie F. Uy, et al.
Published: (2022-08-01)

Role of HER2 in NSCLC
by: Kun ZHANG, et al.
Published: (2015-10-01)

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
by: Lena-Christin Conradi, et al.
Published: (2019-09-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Evolving Treatment Landscape of <i>HER2</i>-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
by: Ioannis A. Vathiotis, et al.
Published: (2023-02-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
by: Xiaoqing Cai, et al.
Published: (2022-06-01)

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
by: Elizabeth Rubin, et al.
Published: (2024-01-01)

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
by: Zaid Sirhan, et al.
Published: (2022-07-01)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
by: Paula González-Alonso, et al.
Published: (2015-08-01)

The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions
by: Saleh Alrhmoun, et al.
Published: (2022-12-01)

HER2-Low Breast Cancer: Current Landscape and Future Prospects
by: Shirman Y, et al.
Published: (2023-08-01)

Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo
by: Siao-Syun Guan, et al.
Published: (2018-06-01)

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)
by: Guangjian Yang, et al.
Published: (2022-08-01)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01)

HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
by: Xin Yu, et al.
Published: (2022-03-01)

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
by: Alexander Rau, et al.
Published: (2021-01-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-05-01)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
by: Simon Peter Gampenrieder, et al.
Published: (2021-12-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

Ultrasensitive assay of HER1, HER2, and heregulin-α in whole blood
by: Raluca-Ioana Stefan-van Staden, et al.
Published: (2022-12-01)

Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
by: Jenny Karlsson, et al.
Published: (2023-06-01)

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
by: Sun J, et al.
Published: (2022-07-01)

Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity
by: Lei Wang, et al.
Published: (2020-10-01)

Minimal HER1 and HER2 expressions in CHO and HEK-293 cells cause them appropriate negative cells for HERs-related studies
by: Abasalt Hosseinzadeh Colagar, et al.
Published: (2013-11-01)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
by: Guo-dong Cao, et al.
Published: (2017-12-01)

HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA
by: Jack D. Godfrey, et al.
Published: (2022-08-01)

Ekspresi HER2/neu(c-ErbB2) pada Kanker Kolorektal
by: Nita Afriani, et al.
Published: (2014-12-01)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
by: Patrik Pöschke, et al.
Published: (2023-09-01)

Editorial: Cancer treatment and early detection targeting HER receptors, Volume II
by: Xiaoqing Cai, et al.
Published: (2023-06-01)

A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
by: Shuling Zhou, et al.
Published: (2023-01-01)

Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital
by: Lilian Bringolf, et al.
Published: (2016-12-01)